SCHEMBL30765502

SCHEMBL30765502

O=C(Cn1c(-c2ccccc2)ncc(NC(=O)CCCc2ccc(Oc3ccccc3)cc2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.40
NTRK1 P04629 2/20 0.38
PLAAT3 P53816 1/20 0.38
PLAAT5 Q96KN8 1/20 0.38
PLAAT2 Q9NWW9 1/20 0.38
PLAAT4 Q9UL19 1/20 0.38
ELANE P08246 3/20 0.38
KDM6B O15054 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
F2 P00734 5/20 0.37
P2RX3 P56373 1/20 0.37
DGAT2 Q96PD7 1/20 0.37
AVPR1B P47901 1/20 0.37
NTRK3 Q16288 1/20 0.37
CMA1 P23946 1/20 0.37
CTRC Q99895 1/20 0.37
PRSS1 P07477 1/20 0.36
NAMPT P43490 1/20 0.36
F3 P13726 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765489 0.92 F2 (0.39) CASP1NTRK1ELANEKDM6BKDM4C
SCHEMBL30765955 0.89 TDP1 (0.40) CASP1NTRK1ELANEAVPR1BNTRK3
SCHEMBL30765697 0.89 F2 (0.43) CASP1NTRK1ELANEKDM6BKDM4D
SCHEMBL30765974 0.88 CASP1 (0.44) CASP1NTRK1ELANEAVPR1BNTRK3
SCHEMBL30765437 0.87 HDAC6 (0.41) ELANEF2CMA1CTRCPRSS1
SCHEMBL30765550 0.86 F2 (0.38) CASP1NTRK1ELANEF2AVPR1B
SCHEMBL30765886 0.84 CASP1 (0.40) CASP1NTRK1ELANEAVPR1BNTRK3
SCHEMBL30765820 0.84 CMA1 (0.40) NTRK1ELANEF2CMA1CTRC
SCHEMBL30765583 0.84 F2 (0.40) NTRK1KDM6BKDM4CF2NTRK3
SCHEMBL30765821 0.84 NTRK1 (0.39) CASP1NTRK1ELANEF2AVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed